反应详情

2-(1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol was reacted with 1-(phenylsulfonyl)-1H-indol-3-ylboronic acid via General Procedure B to give intermediate 2-(1-((9-methyl-6-morpholino-2-(1-(phenylsulfonyl)-1H-indol-3-yl)-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol. The intermediate was suspended in MeOH (3 mL) whereupon 3N KOH (0.3 mL) was added and the reaction mixture was heated at 50° C. for several hours until the protecting group was removed. Reverse phase purification gave 115. MS (Q1) 490.3 (M)+. 1H NMR (400 MHz, DMSO) δ 11.46 (s, 1H), 8.67-8.51 (m, 1H), 8.13 (d, 1H), 7.53-7.25 (m, 2H), 7.20-7.07 (m, 2H), 4.27 (s, 4H), 4.02 (s, 1H), 3.84 (s, 3H), 3.76 (dd, 12.2, 4H), 3.69 (s, 2H), 2.88 (d, 2H), 1.97 (t, 2H), 1.66 (d, 2H), 1.21 (dt, 3H), 1.02 (s, 6H)